In a study published in PNAS, a research team led by SHI Xinghua from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences, in collaboration with GAO Huajian's ...
Fragment-based drug discovery has delivered multiple FDA-approved drugs including capivasertib, the first-in-class AKT inhibitor co-developed by the ICR, Astex and AstraZeneca. Despite the track ...
Our study found that PZ biopsies offer no additional benefit for TZ lesion tumors, and increasing the number of cores in the TZ region can compensate for the current limitations of TZ biopsies. These ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback